ADA Scientific Sessions 2026 Abstract

ABK-GIPR-1, an Oral Small-Molecule GIPR Antagonist, Enhanced GLP-1RA’s Efficacy in Reducing Body Weight and Improving Metabolic Profile in Preclinical Obesity Models

By Shengnan Liu, Weijia Lu, Yue Li, Haiyan Ying

Experiments in animalsInterventions

The paper

Shengnan Liu, Weijia Lu, Yue Li, Haiyan Ying

Shanghai

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, late-breaking 3070-LB

doi.org/10.2337/db26-3070-lb

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
JCI Insight6 Oct 2026
Antibody reduced fat while preserving lean mass in mice
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity